Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
BLCO Bausch + Lomb Corp.
15.850
+0.340+2.19%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-- 156.7596 -10.78% 162.1289 -10.78% 162.1289 -- 154.5801
Receivable Turnover(T)
-- 5.1194 9.7% 5.5124 9.7% 5.5124 -- 5.6611
Inventory Turnover(T)
-- 2.4783 16.09% 2.4697 16.09% 2.4697 -- 2.3663
Fixed Assets Turnover(T)
-- 3.08 -0.19% 3.1519 -0.19% 3.1519 -- 3.1265
Total Asset Rate(T)
-- 0.3459 13.57% 0.3409 13.57% 0.3409 -- 0.336
ROIC
-- 1.858% 1030.25% 1.891% 1030.25% 1.891% -- -0.844%
ROE
-- 2.451% 1144.28% 1.891% 1144.28% 1.891% -- -0.836%
ROA
-- 1.605% 1140.34% 1.648% 1140.34% 1.648% -- -0.707%
FCF to Sales
-- 12.775% 128.8% 17.636% 128.8% 17.636% -- 17.125%
FCF to Net Income
-- 275.429% -- 364.835% -- 364.835% -- --
Efficiency Ratios
Profitability Ratios TTM
Gross Margin
-- 60.721% -2.09% 61.036% -2.09% 61.036% -- 61.327%
Operating Margin
-- 8.216% 14.46% 9.057% 14.46% 9.057% -- 9.142%
Net Margin
-- 4.638% 1016.4% 4.834% 1016.4% 4.834% -- -2.104%
EBITDA Margin
-- 0.19% -3.78% 0.2008% -3.78% 0.2008% -- 0.205%
R & D Expense Ratio
-- 7.580% -11.04% 7.330% -11.04% 7.330% -- 7.520%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-- 31.092% -- -- -- -- -- --
Total Assets to Common Equity
-- 152.759% 2.13% 116.015% 2.13% 116.015% -- 118.359%
Debt to Asset Ratio
-- 31.933% -- -- -- -- -- --
Current Ratio
-- 1.5742 -18.24% 1.4877 -18.24% 1.4877 -- 1.3888
Quick Ratio
-- 0.8489 -16.16% 0.8144 -16.16% 0.8144 -- 0.6984
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- 0.901% -- -- -- --
Net Income CAGR(3Y)
-- -- -- -36.476% -- -- -- --
FCF 1 Year Growth
-- -- 365.11% 152.472% -- -- -- --
FCF CAGR(3Y)
-- -- -- 0.101% -- -- -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments and treatments for various eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases; and and contact lenses for therapeutic use. The Surgical segment provides medical device equipment, consumables, and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions. The company was founded in 1853 and is headquartered in Vaughan, Canada.
CEO: Papa, Joseph C.
Market: NYSE
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top